initi buy pt catalyst-
rich store
interest stori key potenti catalyst next month
biopharmaceut compani leverag
proprietari develop platform build pipelin near medium long-
term valu driver near term gener forteo osteoporosi
repres signific rel durabl cash flow stream particularli
compani secur favor therapeut equival rate
forteo late-stag partner program buy merck
nr could materi valu driver medium/long term
proprietari pfenex express platform enabl addit opportun
longer term via partnership intern develop program
gener forteo could signific revenu contributor
advanc asset gener version
nr forteo recent approv fda forteo sale
us outsid us pfenex first
far compani receiv fda approv gener version forteo
seek therapeut equival rate forteo would
allow product automat substitut forteo manag
sound confid success view complex regulatori pathway
limit competit us estim target assum
compani secur rate determin fda could immin
program could drive medium/long-term growth
partner intend
improv version jazz erwinaz acut lymphoblast leukemia
theoret market potenti high prioriti
could get market pfenex util
pneumococc vaccin could get market
serum institut india siipl privat pneumosil launch year
receiv low single-digit royalti vaccin could
repres signific stream given size pneumococc vaccin
market nr prevnar sale
proven platform gener intern extern opportun
util express technolog platform produc improv
version protein peptid enzym compani identifi
opportun believ somewhat de-risk could develop
partnership
valuat risk
pt base dcf analysi wacc termin growth
downsid risk includ lower sale failur secur rate
failur product get market lower sale
partner product
tr target
launch materi
share gener market
revenu
yield royalti
captur global
royalti
alvogen launch
us a-rat
launch ag gener
price discount
captur forteo
market gener
competit increas
pressur share
price
discount revenu
launch
lead resumpt
reach yield
sale royalti
launch
captur global
vaccin market yield
royalti
receiv a-
reach
gener competit
increas reduc
share gener
market
revenu
get market
get market
page
background
focus develop improv peptid protein-bas
therapeut vaccin proprietari pfenex express technolog platform
technolog origin develop within chemic compani buy jame sheehan
spun compani remain privat held ipo
immedi opportun partner alvogen privat launch gener version
forteo us sale could signific durabl cash flow gener
leverag proprietari develop platform build pipelin near medium long-
term valu driver near term gener forteo repres signific rel durabl
cash flow stream particularli compani secur favor therapeut equival rate
forteo late-stag partner program merck could materi valu driver
medium/long term proprietari pfenex express platform could enabl addit opportun
longer term via partnership intern develop program
page
posit announc phase mileston fda approv mileston pfenex inc
gener forteo could signific revenu contributor
advanc asset gener version lli forteo teriparatid recent
approv fda market forteo recombin version human parathyroid hormon pth
treatment osteoporosi postmenopaus woman high risk fractur forteo sale
us outsid us pfenex first far compani
receiv fda approv gener version forteo
commerci partner alvogen plan launch us fda make
determin therapeut equival compani seek rate would allow
automat substitut pharmaci forteo conduct sever human factor
studi support rate recent demonstr user interfac
non-inferior forteo formal timelin fda make decis
believ high prioriti agenc sound confid secur rate
view receipt rate would trigger mileston payment well higher gross
profit split alvogen vs without rate
base case assumpt alvogen launch us a-rat
launch author gener ag gener enter market assum
gener price discount captur forteo market
ag split gener market share model addit gener competit
emerg pressur share model declin gener market
price model price discount rise assumpt yield revenu
figur
figur potenti revenu pfenex us sale base case
assum brand forteo gross margin gener cog similar brand cog receiv
gross profit split product therapeut equival a-rat forteo otherwis
complex regulatori pathway limit competit us
recombin peptid forteo challeng product generic fda requir compani
seek approv gener peptid produc recombin process file nda
support clinic data immunogen altern compani use abbrevi new
drug applic anda pathway gener peptid produc synthet process certain criteria
met teva pharmaceut teva hold apotex privat seek approv synthet
version via anda pathway pursu approv recombin product via
nda pathway
teva note earn call continu work fda gforteo note
success launch could occur late statu apotex gener applic
unknown
page
penetr market gross gross profit share gross pfenex inc
gener forteo launch geographi could add addit valu
addit us market alvogen develop commerci right
european union eu middl east north africa mena certain territori rest world
exclud mainland china hong kong singapor malaysia thailand
commerci right latter region china nt pharma group compani limit
nr could earn mileston agreement receiv
gross profit sale alvogen territori double-digit royalti sale nt
forteo sale europ unlik us market gener competit alreadi
emerg europ gedeon richter privat launch biosimilar version forteo eastern europ
august forteo regul biolog eu gedeon richter licens right
biosimilar rest europ stada saz-d nr also launch august
anticip approv eu
figur collabor region
row exclud mainland china hong kong singapor malaysia thailand licens nt pharma
high prioriti partner fda
pharmaceut enter collabor agreement
develop commerci recombin erwinia
asparaginas long-act erwinia asparaginas develop
product candid altern erwinaz asparaginas erwinia chrysanthemi market
treatment acut lymphoblast leukemia pediatr patient develop
hypersensit coli-deriv asparaginas erwinaz current drug approv
key pipelin asset reflect signific econom
collabor receiv mileston payment far could receiv
addit payment includ relat develop mileston tie
regulatori event sale mileston figur compani also receiv tier
royalti sale rang mid high singl digit
figur econom collabor
page
partnerregionmilestonesprofit split/royaltiescommentsalvogen theramex gross profit-maa review potenti approv partner theramex commerci europ switzerlandalvogen sajamenaup gross profit-maa submit saudi arabia octob partner saja commercializealvogen pharmbio koreasouth koreaup gross profit-alvogen partner pharmbio korea commercializealvogen jamp pharma canadaup gross profit-alvogen partner jamp pharma commercializealvogen kamadaisraelup gross profit-alvogen partner kamada commercializealvogenrow gross profitnt pharmachina hong kong singapor malaysia double-digit royalti salesdevelop single-digit pfenex inc
approxim patient develop year us around half case occur pediatr
patient age make common childhood cancer anoth case occur
adolesc young adult aya popul age patient treat standard
chemotherapi regimen contain coli-deriv asparaginas hypersensit reaction
requir treatment erwinaz
launch erwinaz sale ramp quickli sinc
volatil due suppli challeng figur market erwinaz via licens agreement porton
biopharma limit pbl privat compani own uk govern pbl receiv fda
warn letter experienc on-going challeng manufactur erwinaz pbl
notifi februari plan termin licens agreement seek new
partner pbl reach new agreement lose licens sell erwinaz
right sell certain inventori post-termin sale period month
develop manufactur process design overcom qualiti
suppli challeng erwinaz promis provid reliabl suppli life-sav treatment
coupl possibl could lose right erwinaz provid strong
invent advanc develop quickli possibl view
manag sound increasingli bullish opportun recent quarter
import note continu believ best commerci partner erwinaz
hope reach agreement pbl also own us regulatori file bla well
file market resolv order pbl termin licens find
page
theoret market potenti
produc modern recombin manufactur process much
effici rel erwinaz product time week vs month product
candid also potenti clinic advantag lower immunogen rel
erwinaz dose similarli erwinaz could favor less
frequent dose grant track design fda
success complet phase studi healthi volunt compani initi
enrol single-arm pivot phase studi pediatr adult patient
lymphoblast lymphoma lbl hypersensit coli-deriv asparaginas product
part studi test intramuscular im administr patient part test
intraven iv administr patient expect complet enrol part
although interim analysi patient could acceler timelin posit
compani could submit bla earli
studi enrol pediatr adult patient could lead broader label rel
erwinaz approv base pediatr studi launch erwinaz
plan conduct studi aya popul unabl given suppli constraint
reliabl suppli would also support geograph expans constrain
erwinaz sale peak prior suppli issu without broader use aya
popul geographi success bring market achiev annual sale
estim could receiv royalti base royalti rate
higher scenario annual sale driven use beyond pediatr popul
geographi would yield royalti figur
figur potenti royalti pfenex sale
near-term opportun siipl collabor
non-tox mutant diphtheria toxin use carrier protein vaccin
diphtheria toxin function carrier protein polysaccharid hapten make
immunogen use vaccin make activ use diphtheria toxin
carrier protein prevnar diphtheria toxin tradit manufactur ferment
process develop recombin manufactur process yield cleaner
product potenti fewer side effect cost effect ferment
partner merck serum institut india siipl use pneumococc
vaccin long-tim leader global vaccin market siipl largest vaccin
produc world also sell compani develop prophylact
therapeut vaccin could evolv royalty-bear partnership vaccin advanc
develop import note strain licens siipl
util pneumococc conjug vaccin object
develop pneumococc vaccin broader coverag rel pfe prevnar
lead pneumococc vaccin ww sale conduct broad phase
program adult pediatr patient includ clinic trial figur compani
expect studi read posit file end
fda breakthrough design adult pediatr patient
page
pfenex inc
develop next-gen version prevnar phase trial adult figur
pneumococc conjug vaccin expect phase studi read
plan file fda approv end regulatori applic market
pfe timelin file adult indic similar year-end
ahead pediatr indic account roughli two-third prevnar sale
sever pediatr phase trial on-going recent indic call
expect initi phase studi pediatr patient soon pend discuss regul
believ pneumococc vaccin market winner take market
paper cover fewer pneumococc serotyp rel vs believ
phase data suggest potenti differenti demonstr immunogen
phase across prevnar serotyp includ improv immunogen serotyp
also note pfe phase data adult patient suggest vaccin may lost
benefit prevnar serotyp disagre view believ broader
coverag key differenti yet present data phase studi
pediatr use could import implic market compani plan present
detail result vaccine-rel confer
comment believ prevnar patent present freedom-to-oper issu
believ case previous petit us patent offic inter
part review ipr two prevnar patent expir petit deni
receiv low single-digit royalti sale could repres signific royalti
stream given size pneumococc vaccin market said difficult predict larg
could long revenu stream could last depend part phase data
page
approv time pediatr adult use figur illustr potenti
royalti differ level market share
figur potenti royalti pfenex mrk sale
siipl current two late-stag vaccin candid incorpor first
pneumococc conjug vaccin pneumosil receiv prequalif world
organ decemb second pentaval meningococc conjug vaccin
current phase studi estim complet date june per clinicaltri gov
believ pneumococc vaccin market target siipl could grow
base estim unicef suppli divis receiv tier royalti
low singl digit siipl vaccin sale figur illustr potenti royalti
differ level market share base market royalti
figur potenti royalti pfenex siipl vaccin sale
arcellx collabor biosimilar pipelin could creat valu longer term
arcellx privat enter develop evalu licens agreement
arcellx access pfenex express technolog platform advanc multipl
proprietari sparx protein arcellx explor use sparx protein treatment hematolog
malign activ silenc reprogram antigen-receptor complex t-cell
base therapi product incorpor sparx protein express use pfenex express
technolog compani could receiv mileston payment royalti global sale
also recombin peptid earli develop compani disclos
detail note intend solv signific challeng current therapi pfenex
also biosimilar pipelin could potenti monet partnership figur
page
prevnar ranibizumab lucenti complet extens bioanalyt similar studi compar multipl lot lucenti preclin studi use anim model demonstr similar toler pharmacolog profil pf lucenti phase studi patient wet pegfilgrastim neulasta conduct process develop pegfilgrastim biosimilar candid compani receiv feedback fda support feasibl develop biosimilar pathway pegaspargas oncasparjazz option licens pfenex inc
librari genet engin
pseudomona fluorescen bacteri express strain select via screen process
order produc protein high level yield puriti potenc use librari
coupl high throughput screen order quickli choos optim strain allow robust
protein product compani develop differ peptid protein enzym fusion
protein platform leverag technolog collabor effort
base
addit exist partnership util platform identifi new program
believ somewhat de-risk clinic develop perspect could pursu
new partnership
eef schimmelpennink serv ceo sinc join compani august prior join
serv ceo alvotech previous held variou role hospira
patrick luci act chief busi offic cbo sinc also serv interim ceo
presid januari august prior hire mr schimmelpennink prior serv
cbo mr luci vice-president busi develop market previous
work collabor bioallianc acquir chemic compani
martin brenner dvm phd join compani chief scientif offic cso march prior
mr brenner cso recurs pharmaceut well vice-president head research
earli develop
current conduct search cfo prior cfo susan knudson resign person
reason novemb
page
risk consid
therapeut equival rate key maxim valu
fda rate therapeut equival forteo difficult alvogen
captur meaning share lack therapeut equival would also reduc econom
includ loss mileston payment tie receiv rate lower gross profit share
durabl hard predict
difficult predict addit gener forteo could get market teva apotex
seek approv gener anda pathway teva indic gener
approv could get market late statu apotex applic unknown
could also gener filer entri addit gener competitor would lead pressur
price volum
forteo market shrink
forteo us sale declin sinc competit product launch figur
radiu health nr launch tymlo abaloparatid synthet analog human parathyroid
hormon relat peptid pthrp price tymlo list price wac discount
rel forteo success influenc size forteo pie eat
eros forteo use reduc potenti valu entrant
pth market could also reduc use forteo/gener buy robyn karnauska
ucb ucb-b nr launch even romosozumab list price discount rel
page
could fail get market
due jazz current erwinaz supplier issu schedul contract expir end
repres signific opportun address critic medic need note support
fda seek develop altern erwinaz said fail clinic
would materi downsid estim target
mrk could fail get market could nich product due pfe vaccin
initi broad phase program vaccin base posit phase result
could still clinic risk vaccin lead pfe
vaccin pediatr patient difficult predict larg could long
revenu stream could last depend part phase data
approv time pediatr adult use
model assumpt valuat
target base dcf analysi model sale period determin
termin valu base termin growth rate assumpt underli dcf analysi includ
alvogen launch us a-rat launch ag
gener enter market gener price discount captur
forteo market ag split gener market addit gener
competit emerg pressur share model declin
gener market price model price discount rise
assumpt yield revenu
launch lead resumpt growth erwinaz market
rapid share gain driven greater avail potenti clinic advantag
lower immunogen model market share rise
yield sale similar erwinaz peak sale royalti
launch captur global pneumococc conjug
vaccin market yield royalti assum royalti rate
siipl launch pneumosil captur share within target market primarili
develop nation yield royalti assum royalti
assum termin growth rate discount after-tax profit back end
believ approxim compani weight averag cost capit
figur summar estim figur summar dcf analysi
page
page
 changetot revenuegross after-tax work cash flow sharedcf sensit discount rate termin growth rate current ratetermin cash growth pfenex inc
forteo gener penetr share
estim reflect gener penetr market share assumpt view feasibl
a-rat gener evalu downsid scenario secur a-rat
scenario model gener penetr reach vs base
case vs base case assum launch author
gener ag earli similar base case assum addit gener competit
emerg reduc share gener forteo market scenario
would reduc annual gross profit contribut theoret dcf
valu
figur potenti revenu pfenex us sale downsid case
assum brand forteo gross margin gener cog similar brand cog receiv
gross profit split product therapeut equival a-rat forteo otherwis
base case model assum exclus follow addit forteo gener
lead signific pressur market share price also consid upsid scenario
addit forteo gener launch materi scenario would increas annual
gross profit contribut theoret dcf valu
year addit gener launch delay would add theoret dcf
figur potenti revenu pfenex us sale upsid case
assum brand forteo gross margin gener cog similar brand cog receiv
gross profit split product therapeut equival a-rat forteo otherwis
page
penetr market gross gross profit share gross penetr market gross gross profit share gross pfenex inc
assum launch sale reach similar prior
peak sale erwinaz base resumpt growth erwinaz market strong share gain
note potenti clinic advantag could lead greater convers
erwinaz market higher sale scenario sale reach would add
theoret dcf valu downsid scenario fail get market would
reduc theoret valu
difficult predict larg could long revenu stream could last
depend part phase data approv time pediatr adult
use base case model assum launch captur
pneumococc conjug vaccin market also evalu sever addit scenario
model share reach maintain pneumococc conjug vaccin market
would add theoret dcf valu scenario share reach one
year return launch would add theoret valu
downsid scenario fail get market captur materi share market
would reduc theoret valu
page
page
potenti launchestimingcommentssiipl pneumosil pneumococc conjug vaccin incorpor achiev prequalif world organ decemb receiv tier royalti low singl digit siipl vaccin version lli forteo teriparatid approv us forteo sale us pfenex first far compani receiv fda approv gener version forteo commerci partner alvogen plan launch us fda make determin therapeut equival compani seek rate would allow automat substitut forteo anticip approv eu forteo sale europ unlik us market gener competit alreadi emerg europ gedeon richter privat launch biosimilar version forteo eastern europ august forteo regul biolog eu gedeon richter licens right biosimilar rest europ stada saz-d nr also launch august erwinia asparaginas partner develop altern erwinaz market treatment acut lymphoblast leukemia pediatr patient develop hypersensit coli-deriv asparaginas erwinaz current drug approv patient popul potenti mileston decis therapeut equival rate readout conduct broad phase program pneumococc conjug vaccin adult pediatr patient incorpor expect studi read posit file end receiv low single-digit royalti sale phase readout expect phase studi pneumococc conjug vaccin read compani plan file fda approv plan initi phase studi pediatr indic call expect initi phase studi pediatr patient soon pend discuss regul phase data pediatr plan present detail data phase studi pediatr patient vaccine-rel confer fda approv teva gener seek approv synthet gforteo product via anda pathway teva indic earn call expect approv prior expect complet enrol phase studi interim analysi could come conduct single-arm pivot phase studi pediatr adult patient lymphoblast lymphoma lbl hypersensit coli-deriv asparaginas product expect complet enrol part although interim analysi patient could acceler timelin posit compani could submit bla earli plan file fda approv plan file fda approv pfenex inc
view manag compens appear align investor interest name execut
offic elig earn incent bonu subject compani achiev corpor
perform goal individu achiev corporate-level goal includ continu
develop product candid certain corpor oper metric specifi
compens committe determin achiev corpor attain goal
figur summari manag compens
page
name posit yearsalarybonusopt awardsstock awardsnon-equ incent compensational compensationtotalevert presid busi pfenex inc
page
incomepre-tax incomenet incomeadjust ep pfenex inc
page
pfenex inc
page
 us ex-u us ex-u us ex-u product us ex-u revenuetot us ex-u us ex-u us ex-u milestones/othernmnmnmnmnmtot product us ex-u revenuetot us ex-u us ex-u us ex-u product us ex-u revenuetot pfenex inc
page
 us ex-u revenuetot gross us ex-u revenuetot gross pfenex inc
page
marketforteo penetr market profit share gross marketseuropeforteo penetr price discountgener market sharegross profitgross margingross profit share gross profitrow ex-chinaforteo ex-u sale rowforteo row salesgener penetr price discountgener market sharegross profitgross margingross profit gross profit split pfenex inc
page
row nt pharma forteo row sale china/ row forteo china/ row salesgener penetr price discountgener market shareroyalti royalti total ex-u revenu collabor erwinaz shareroyalti royalti vaccin carrier protein pfe prevnar prevnar penetr salesroyalti royalti royalti usroyalti us royalti ex-usroyalti ex-ussiimarket growthsii market royalti pfenex inc
page
 us ex-u us ex-u us ex-u product us ex-u us ex-u us ex-u milestones/othernmnmnmnmnmtot us ex-u milestones/othernmnmnmnmnmtot product us ex-u revenuenmnmnmnmtot us ex-u us ex-u us ex-u product us ex-u pfenex inc
page
 us ex-u gross us ex-u gross pfenex inc
page
marketforteo penetr market profit share gross marketseuropeforteo penetr market profit share gross ex-chinaforteo ex-u sale row penetr market profit profit pfenex inc
page
row nt pharma forteo row sale china/ china/ row penetr market ex-u revenu collabor erwinaz royalti vaccin carrier protein pfe prevnar prevnar penetr royalti royalti market royalti pfenex inc
statement balanc sheet
page
statementgaap net loss intang compens oper work flow invest flow repurchas common repay capit leas payment relat issuanc financ flow foreign exchang equival increas equival sheetcash unbil receiv tax current current long term asset portion defer current current revenu less current long-term stockhold liabil stockhold pfenex inc
focus develop improv peptid protein-bas
therapeut vaccin proprietari pfenex express technolog platform
technolog origin develop within chemic compani spun
compani remain privat held ipo immedi
opportun partner alvogen privat launch gener version forteo us
sale could signific durabl cash flow gener
leverag proprietari develop platform build pipelin near medium
long-term valu driver near term gener forteo repres signific rel
durabl cash flow stream particularli compani secur favor therapeut equival
rate forteo late-stag partner program merck could materi valu driver
medium/long term proprietari pfenex express platform could enabl addit
opportun longer term via partnership intern develop program
valuat risk
pt base dcf analysi wacc termin growth rate downsid risk
includ lower sale failur secur rate failur get market
lower sale failur partner product get market lower sale
compani mention note
compani rate
serum institut india privat ltd privat
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
